BNP Paribas Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $130M | Sell |
|
|||||
|
2025
Q1 | $139M | Buy |
|
|||||
|
2024
Q4 | $129M | Buy |
|
|||||
|
2024
Q3 | $94.5M | Buy |
|
|||||
|
2024
Q2 | $108M | Sell |
|
|||||
|
2024
Q1 | $109M | Buy |
|
|||||
|
2023
Q4 | $94.9M | Buy |
|
|||||
|
2023
Q3 | $76.3M | Buy |
|
|||||
|
2023
Q2 | $62M | Buy |
|
|||||
|
2023
Q1 | $62M | Buy |
|
|||||
|
2022
Q4 | $65.9M | Buy |
|
|||||
|
2022
Q3 | $56.7M | Buy |
|
|||||
|
2022
Q2 | $43.7M | Buy |
|
|||||
|
2022
Q1 | $33.7M | Sell |
|
|||||
|
2021
Q4 | $31.7M | Sell |
|
|||||
|
2021
Q3 | $37.6M | Sell |
|
|||||
|
2021
Q2 | $38.2M | Buy |
|
|||||
|
2021
Q1 | $31.5M | Buy |
|
|||||
|
2020
Q4 | $24.7M | Sell |
|
|||||
|
2020
Q3 | $25.4M | Buy |
|
|||||
|
2020
Q2 | $27M | Sell |
|
|||||
|
2020
Q1 | $20.4M | Buy |
|
|||||
|
2019
Q4 | $21.8M | Sell |
|
|||||
|
2019
Q3 | $26.9M | Sell |
|
|||||
|
2019
Q2 | $34.2M | Buy |
|
|||||
|
2019
Q1 | $32.3M | Buy |
|
|||||
|
2018
Q4 | $12.4M | Sell |
|
|||||
|
2018
Q3 | $23.7M | Sell |
|
|||||
|
2018
Q2 | $24.2M | Buy |
|
|||||
|
2018
Q1 | $9.1M | Sell |
|
|||||
|
2017
Q4 | $19.5M | Sell |
|
|||||
|
2017
Q3 | $32M | Buy |
|
|||||
|
2017
Q2 | $17.9M | Buy |
|
|||||
|
2017
Q1 | $9.06M | Buy |
|
|||||
|
2016
Q4 | $7.17M | Buy |
|
|||||
|
2016
Q3 | $8.65M | Sell |
|
|||||
|
2016
Q2 | $8.33M | Buy |
|
|||||
|
2016
Q1 | $2.34M | Buy |
|
|||||
|
2015
Q2 | – | Sell |
|
|||||
|
2015
Q1 | $684K | Sell |
|
|||||
|
2014
Q4 | $421K | Buy |
|
|||||
|
2013
Q4 | – | Sell |
|
|||||
|
2013
Q3 | $2.08M | Sell |
|
|||||
|
2013
Q2 | $3.22M | Buy |
|